Evelo Biosciences, Inc. Annual Operating Income (Loss) in USD from 2016 to 2022

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Evelo Biosciences, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2016 to 2022.
  • Evelo Biosciences, Inc. Operating Income (Loss) for the quarter ending September 30, 2023 was -$11.2M, a 61.5% increase year-over-year.
  • Evelo Biosciences, Inc. Operating Income (Loss) for the twelve months ending September 30, 2023 was -$76.7M, a 33.2% increase year-over-year.
  • Evelo Biosciences, Inc. annual Operating Income (Loss) for 2022 was -$108M, a 6.01% increase from 2021.
  • Evelo Biosciences, Inc. annual Operating Income (Loss) for 2021 was -$115M, a 25.6% decline from 2020.
  • Evelo Biosciences, Inc. annual Operating Income (Loss) for 2020 was -$91.9M, a 6.4% decline from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$108M +$6.93M +6.01% Jan 1, 2022 Dec 31, 2022 10-K 2023-03-16
2021 -$115M -$23.5M -25.6% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-16
2020 -$91.9M -$5.53M -6.4% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-24
2019 -$86.4M -$28.3M -48.6% Jan 1, 2019 Dec 31, 2019 10-K 2021-03-09
2018 -$58.1M -$30.6M -111% Jan 1, 2018 Dec 31, 2018 10-K 2020-02-14
2017 -$27.5M -$14.5M -111% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-14
2016 -$13M Jan 1, 2016 Dec 31, 2016 10-K 2019-02-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.